Ventures focusing on drug testing or therapies against rare disease, cancer, gastrointestinal disease, fibrosis and pain are among those selected by the editors in 2014’s crop of startups. I n 2014, the biotech sector posted the largest ever influx of private funding since Nature Biotechnology was founded—a total of $9 bil- lion, up 50% from the previous year. At the same time, the past two years have seen more exits through initial public offerings (IPOs) and trade sales than any other two-year period. Eyepopping valuations totaling over $100 million have been obtained for several firms with preclinical stage technology. What were the cutting-edge biotech ventures that raised venture funding during this bumper year?
Mendeley saves you time finding and organizing research
Choose a citation style from the tabs below